The Trustees of Columbia University in the City of New York;The Research Foundation for The State University of New York
发明人:
Cohen, Ira S.,Brink, Peter R.,Rosen, Michael R.
申请号：
AU2017238505
公开号：
AU2017238505A1
申请日:
2017.03.23
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
A method of treating cancer in vivo includes introducing in vitro into human mesenchymal stem cells (hMSCs) at least one type of inhibitory oligonucleotide, and contacting a tumor tissue of syncytial cancer cells with the hMSCs in vivo under conditions permitting a hMSC to form a gap junction channel with a first syncytial cancer cell of the tumor tissue. As a result, the at least one type of inhibitory oligonucleotide is delivered into the first syncytial cancer cell by traversing the gap junction channel and the at least one type of inhibitory oligonucleotide is delivered into a second syncytial cancer cell of the tumor tissue by traversing a gap junction channel between the first syncytial cancer cell and the second syncytial cancer cell.
